Organon & Co.

Health Care
Biotechnology: Pharmaceutical Preparations
www.organon.com

Earnings Score
Safety Score

Market Cap $2.35B
PE 3
Debt $8.98B
Cash $547.00M
EV $10.78B
FCF $777.00M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$750.00M
EBIT	$672.00M
ROE	138%
ROA	5%
FCF	$777.00M
Equity	$542.00M
Growth Stability	41%
PE	3.14
PEG	-0.18
PB	4.34
P/FCF	3.03
P/S	0.37
Price/Cash	0.23
Debt/Equity	16.56
Debt/FCF	11.55
Net Margins	6%
Gross Margins	57%
Op. Margins	11%
Earnings CAGR	-17%
Sales Growth YoY	-7%
Sales Growth QoQ	-5%
Sales CAGR	-0%
FCF CAGR	-27%
Equity CAGR	-25%
Earnings Stability	-0.12
Earnings Growth YoY	-57%
Earnings Growth QoQ	-20%

Earnings CAGR 5Y	-17%
Sales CAGR 5Y	-0%
FCF CAGR 5Y	-27%
Equity CAGR 5Y	-27%
Earnings CAGR 3Y	1%
Sales CAGR 3Y	1%
FCF CAGR 3Y	15%
Equity CAGR 3Y	45%
Market Cap	$2.35B
Revenue	$6.29B
Dividend Yield	13%
Payout Ratio	40%
Assets	$13.16B
Total Debt	$8.98B
Cash	$547.00M
Shares Outstanding	257.86M
EV	10.78B
Earnings Score	6%
Safety Score	30%
Working Capital	1.76B
Current Ratio	1.67
Gross Profit	$3.60B
Shares Growth 3y	1%
Equity Growth QoQ	15%
Equity Growth YoY	1K%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Geographically, it derives a majority of revenue from Europe and Canada.

SEC Filings

Direct access to Organon & Co. (OGN) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2025
- 10-Q Mar 31
2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Organon & Co. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Organon & Co. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -17%

Stability -12%

loading chart...

Organon & Co. Discounted Cash Flow

Fully customizable DCF calculator online for Organon & Co..

Years

Calculation mode

= $1.7B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$777M	$570M	$418M	$306M	$225M	$165M	$121M	$89M	$65M	$48M	$35M	$350M
DCF		$518M	$345M	$230M	$154M	$102M	$68M	$45M	$30M	$20M	$13M	$135M
Value	$1.7B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	41%	33%	21%	15%	16%	13%	6%
ROA	-	27%	14%	10%	6%	6%	5%
ROE	-	39%	-90%	-103%	-1K%	183%	138%

Bad Net Margins (5.75%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	0	4.65	13.48	16	11.65	11.55
Debt over Equity	-	0	-6.06	-10	-125.27	18.86	16.56
Growth Stability	-	-	-	41%	69%	79%	41%

Bad Debt/FCF ratio (11.55)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Bad Debt/Equity ratio (16.56)

The company is overleveraged and has a bad balance between equity and debt.

Bad Graham’s Stability (41%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	-16%	-3%	-2%	1%	2%	-0%
Earnings YoY growth	-	-33%	-37%	-32%	12%	-16%	-17%
Equity YoY growth	-	-22%	-127%	-41%	-92%	-774%	-27%
FCF YoY growth	-	-31%	-3%	-66%	-17%	39%	-27%